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Common variable immunodeficiency (CVID) is increasingly recognized for its associ-
ation with autoimmune and inflammatory complications. Despite recent advances in 
immunophenotypic and genetic discovery, clinical care of CVID remains limited by our 
inability to accurately model risk for non-infectious disease development. Herein, we 
demonstrate the utility of unbiased network clustering as a novel method to analyze 
inter-relationships between non-infectious disease outcomes in CVID using databases 
at the United States Immunodeficiency Network (USIDNET), the centralized immuno-
deficiency registry of the United States, and Partners, a tertiary care network in Boston, 
MA, USA, with a shared electronic medical record amenable to natural language pro-
cessing. Immunophenotypes were comparable in terms of native antibody deficiencies, 
low titer response to pneumococcus, and B cell maturation arrest. However, recorded 
non-infectious disease outcomes were more substantial in the Partners cohort across 
the spectrum of lymphoproliferation, cytopenias, autoimmunity, atopy, and malignancy. 
Using unbiased network clustering to analyze 34 non-infectious disease outcomes 
in the Partners cohort, we further identified unique patterns of lymphoproliferative 
(two clusters), autoimmune (two clusters), and atopic (one cluster) disease that were 
defined as CVID non-infectious endotypes according to discrete and non-overlapping 
immunophenotypes. Markers were both previously described {high serum IgE in the 
atopic cluster [odds ratio (OR) 6.5] and low class-switched memory B cells in the total 
lymphoproliferative cluster (OR 9.2)} and novel [low serum C3 in the total lymphoprolif-
erative cluster (OR 5.1)]. Mortality risk in the Partners cohort was significantly associated 
Abbreviations: AIE, autoimmune enteropathy; AIHA, autoimmune hemolytic anemia; AIN, autoimmune neutropenia; CVID, 
common variable immunodeficiency; EMR, electronic medical record, GLILD, granulomatous-interstitial lung disease; IBD, 
inflammatory bowel disease; ITP, immune thrombocytopenia; LAD, lymphadenopathy; NRH, nodular regenerative hyperpla-
sia; PH, pulmonary hypertension; USIDNET, United States Immunodeficiency Network.
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with individual non-infectious disease outcomes as well as lymphoproliferative cluster 
2, specifically (OR 5.9). In contrast, unbiased network clustering failed to associate 
known comorbidities in the adult USIDNET cohort. Together, these data suggest that 
unbiased network clustering can be used in CVID to redefine non-infectious disease 
inter-relationships; however, applicability may be limited to datasets well annotated 
through mechanisms such as natural language processing. The lymphoproliferative, 
autoimmune, and atopic Partners CVID endotypes herein described can be used 
moving forward to streamline genetic and biomarker discovery and to facilitate early 
screening and intervention in CVID patients at highest risk for autoimmune and inflam-
matory progression.
Keywords: common variable immunodeficiency, non-infectious complications, endotypes, atopy, autoimmunity, 
lymphoproliferation, unbiased network clustering
inTrODUcTiOn
Common variable immunodeficiency (CVID) is the most fre-
quent symptomatic primary immune deficiency worldwide (1, 2). 
The diagnosis requires low immunoglobulin levels (low IgG in 
combination with low IgA and/or low IgM for age-matched refer-
ence range), a demonstration of poor antibody-specific response 
to antigen challenge, and the exclusion of secondary causes. 
Historically, the clinical presentation of CVID centered around 
predisposition to recurrent infections; however, the definition has 
more recently expanded to include autoimmunity or lymphopro-
liferation as primary clinical presentations (1).
CVID epidemiology has been described almost exclusively 
at large national referral centers and centralized databases such 
as the United States Immunodeficiency Network (USIDNET). 
These data demonstrate the high prevalence of inflammatory 
and autoimmune complications in CVID, with non-infectious 
disease outcomes previously estimated at 68–74% and associ-
ated with up to an 11-fold increase in patient mortality (3–5). 
The national burden of CVID is also substantial and was recently 
estimated at US $274,200 per patient annually (6). Models for 
cost reduction include facilitating an earlier diagnosis as well 
as reducing rates of premature death in CVID patients with 
infiltrative lymphocytic complications, specifically (6, 7).
Substantial research effort over the last decade has centered 
around trying to identify the CVID subset that will develop 
inflammatory and autoimmune complications. To date, this 
research has primarily focused on specific non-infectious disease 
outcomes, including lymphadenopathy (LAD), splenomegaly, 
autoimmune cytopenias, and organ-specific lymphoproliferative 
disease (5, 8–17). The Freiburg (8), Paris (9), and EUROclass 
(10) trials were the first to use peripheral B cell flow cytometry to 
subcategorize CVID, which successfully identified low number of 
class-switched memory B cells as a marker for lymphoproliferative 
disease. More recently, defects in the T cell compartment includ-
ing low total CD4+ T cells as well as reduced numbers of naïve 
CD4+ and CD8+ T cells have been associated with increased risk 
for specific autoimmune and lymphoproliferative complications 
including autoimmune cytopenias (13, 17), enteropathy (11, 17), 
and granulomatous-interstitial lung disease (GLILD) (15). 
Reclassification of this CVID subset as late-onset combined 
immunodeficiency has been proposed (11). Finally, lymphopro-
liferative pathology and progressive GLILD specifically have been 
correlated with high serum IgM (5, 14). However, an unbiased 
approach to categorizing the full spectrum of non-infectious 
disease complications seen in CVID has been lacking in the field. 
Moreover, CVID sub-classification using the Freiburg, Paris, or 
EUROclass criteria was recently demonstrated to be ineffective in 
determining underlying genetic etiology (18). These data suggest 
that more exact methods of non-infectious disease phenotyping 
in CVID are warranted to facilitate earlier diagnosis and targeted 
therapeutic intervention.
Recent advances in network theory have facilitated novel 
methods for studying biological structures and disease patterns 
(19–22). Unbiased network clustering can elucidate unique 
relationships between seemingly distinct pathophenotypes and 
has proof-of-principle benefit in the discovery of comorbidities 
when applied to human disease (23, 24). As CVID encompasses 
a heterogeneous clinical spectrum with now a growing list of 
diverse causative monogenic mutations (25), we hypothesized 
that network clustering may be uniquely applicable in discerning 
both convergent and divergent patterns of immunopathology 
that associate with risk for autoimmune and inflammatory 
progression.
Herein, we introduce the Partners CVID cohort as a well-anno-
tated tertiary care dataset and perform comparative analysis with 
the USIDNET regarding immunophenotype and non-infectious 
disease outcomes. Using unbiased network clustering, we further 
identify unique patterns of lymphoproliferative, autoimmune, and 
atopic complications in the Partners cohort that are defined as 
CVID non-infectious disease endotypes according to discrete and 
non-overlapping immunophenotypes. These endotypes can be used 
moving forward to streamline genetic and biomarker discovery in 
order to improve non-infectious disease risk modeling in CVID.
MaTerials anD MeThODs
cViD cohort assembly
The USIDNET is a program of the Immune Deficiency 
Foundation. The cohort was assembled by submitting a search 
query for “common variable immunodeficiency” to the USIDNET 
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in 2016. This query yielded 918 patients. We excluded patients 
based on alternative primary diagnoses (combined immuno-
deficiency in 22 cases, transient hypogammagloblulinemia of 
infancy in 7 cases, hemophagocytic lymphohistiocytosis in 3 
cases, autoimmune lymphoproliferative syndrome in 1 case, and 
x-linked lymphoproliferative disease subtype 2 in 1 case). This 
resulted in 884 patients in the USIDNET CVID cohort at the 
time of review.
The Partners CVID cohort was assembled following 
approval by the Partners Institutional Review Board with 
subsequent data collection and analysis performed accord-
ing to the Institutional Review Board-approved protocol. 
A search query for ICD 9 and ICD 10 codes of “common variable 
immunodeficiency” in combination with low total IgG for age-
matched reference range was submitted in 2013 to the Partners 
Research Patient Data Registry, which included clinical data 
from the Brigham and Women’s Hospital, the Massachusetts 
General Hospital, and the Massachusetts General Hospital 
for Children. This initial search query identified 411 patients 
with extractable data in the period of 2006–2013. In further 
chart review, only patients with a diagnosis of CVID by an 
immunologist or confirmatory laboratory evidence of CVID 
were further included, which resulted in 169 patients. From 
2013–2017, new diagnoses of CVID presenting to the Partners 
Allergy/Immunology inpatient or outpatient practices were 
additionally included. This resulted in a total of 205 patients in 
the Partners CVID cohort at the time of review.
scoring of non-infectious Disease 
Outcomes
Non-infectious disease outcomes were scored as annotated 
in the USIDNET. For each patient in the Partners cohort, the 
complete electronic medical record (EMR) was searched across 
clinical notes, laboratory data, radiology, and pathology using the 
web-based natural language processing tool “Queriable Patient 
Inference Dossier” as previously described (26, 27). Extracted 
EMR data were then independently scored for non-infectious 
disease outcomes by direct physician review as detailed below.
End-Organ Infiltrative/Lymphoproliferative Disease
Granulomas and sarcoidosis were defined as biopsy-proven 
disease according to the interpreting pathologist. LAD and 
splenomegaly were defined as radiographic evidence of disease 
and were further subcategorized by biopsy as available. Celiac 
disease was defined by positive serology (anti-tissue transglu-
taminase antibodies) or biopsy-consistent disease according 
to the interpreting pathologist. GLILD was defined as either 
radiographic or biopsy-proven evidence of disease according to 
recent criteria (15, 28). On imaging, a chest computed tomog-
raphy (CT) scan demonstrating bilateral ground-glass opacities 
or 4+ discrete nodules >1  mm in size was scored positive for 
GLILD (29). On either transbronchial or open lung biopsy, 
a report of granulomas, lymphocytic interstitial pneumonia, fol-
licular bronchiolitis, and/or lymphoid hyperplasia was scored as 
positive for GLILD (30); this latter group of patients was further 
subcategorized as biopsy-proven GLILD. Autoimmune hepatitis 
was defined by liver injury in association with positive serology 
(anti-mitochondrial/smooth muscle antibodies) and/or biopsy-
proven evidence of inflammatory pathology in the absence of 
active infection (infiltrating lymphocytes, granulomas, and/or 
regenerative fibrosis) as previously described for CVID (12, 31). 
Patients who met specific pathologic criteria for nodular regen-
erative hyperplasia (NRH) (12, 31) were further subcategorized. 
Autoimmune gastrointestinal disease was defined as chronic 
diarrhea with protein wasting and/or biopsy-proven evidence of 
immune pathology in the absence of active infection. Patients 
were further subcategorized as either autoimmune enteropathy 
(AIE) according to biopsy-proven evidence of cell dropout 
(e.g., parietal or goblet), villous blunting, increased intra-epithe-
lial lymphocytosis, and/or follicular lymphoid hyperplasia, or as 
inflammatory bowel disease (IBD) according to biopsy-proven 
lymphoid aggregates and/or granulomas with a consideration of 
Crohn’s disease or ulcerative colitis in the differential diagnosis 
of the interpreting pathologist as previously described for the 
inflammatory gastrointestinal manifestations of CVID (32). 
Pulmonary hypertension (PH) was defined by positive history on 
physician chart review or otherwise as captured by review of all 
chest CT, echocardiogram, and right heart catheterization data 
in the Partners EMR according to adult criteria as pulmonary 
arterial dilation ≥2.9  cm on chest CT (33), right ventricular 
systolic pressure >30 mmHg on echocardiogram to capture the 
lower limit previously described (34), and/or mean pulmonary 
arterial pressure >25 mmHg at rest on right heart catheteriza-
tion as available (35). Nasal polyps were defined by presence on 
CT scan, direct visualization on rhinoscopy, or biopsy-proven 
disease. When available, biopsy-proven disease was further 
subcategorized as eosinophilic or lymphoproliferative according 
to the interpreting pathologist. Thyroid nodules were defined as 
radiographic evidence of disease.
Cytopenias
Chronic anemia, thrombocytopenia, neutropenia, and lympho-
penia were defined by positive history on physician chart review 
or otherwise as captured by review of all cytology in the Partners 
EMR as total hemoglobin, platelet count, absolute neutrophil 
count, or absolute lymphocyte count less than age-matched refer-
ence range and persistent over >12 months. Chronic cytopenias 
that were presumed iatrogenic or infectious were specifically 
excluded. Cytopenias were further subcategorized as autoimmune 
hemolytic anemia (AIHA), immune thrombocytopenia (ITP), 
or autoimmune neutropenia (AIN) according to a presumed 
diagnosis of exclusion or positive autoantibodies (Coombs, anti-
platelet and/or -neutrophil) as previously described (36–38).
Autoimmune Disease
Psoriasis, alopecia, vitiligo, and chronic intermittent urticaria 
were defined by positive history on physician chart review. 
Inflammatory arthritis was defined as a chart history of rheu-
matoid arthritis (positive rheumatoid factor or anti-cyclic citrul-
linated peptide antibodies), seronegative inflammatory arthritis, 
juvenile idiopathic arthritis, psoriatic arthritis, or inflammatory 
arthritis not otherwise specified with specific exclusion of iso-
lated arthralgias and osteoarthritis. Autoimmune neuropathy was 
defined as a chart history of autoimmune motor or sensory loss 
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and included the diagnoses of non-infectious uveitis, Bell’s Palsy, 
myasthenia gravis, multiple sclerosis, and biopsy-confirmed 
peripheral small fiber polyneuropathy. Autoimmune thyroid dis-
ease was defined as hypothyroidism requiring hormone replace-
ment and was further subcategorized as Hashimoto’s thyroiditis 
(positive anti-thyroperoxidase antibodies). Bronchiectasis was 
defined as radiographic evidence of disease.
Atopic Disease
Asthma, eczema, and allergic rhinitis were defined by positive 
history on physician chart review. Asthma and eczema were 
further subcategorized by Partners subspecialty care (allergy, 
pulmonology, and/or dermatology) and disease severity (e.g., 
intermittent, mild, moderate, or severe). Allergic rhinitis was 
further subcategorized by environmental allergen skin testing 
results as available.
Malignancy
Hematologic malignancy was defined as biopsy-proven leukemia, 
lymphoma, myelodysplasia, multiple myeloma, and/or mastocy-
tosis according to the interpreting pathologist. Solid organ cancer 
was defined by positive history on physician chart review and was 
further subcategorized by anatomic location.
scoring of immunophenotype
Immunophenotype was scored by direct physician review of the 
EMR for each patient in the Partners cohort or as annotated in 
the USIDNET as follows: native immunoglobulin levels (IgG, 
IgA, IgM, IgE, and IgG subclasses 1–4), IgG replacement level 
(median IgG while receiving immunoglobulin replacement 
therapy), total lymphocytes (CD3+, CD4+, CD8+, CD3− 
CD56+ CD16+, and CD19+ as absolute counts on peripheral 
flow cytometry), B cell maturation (CD27+ and CD27+ IgD− as 
percent of CD19+ B cells on peripheral flow cytometry), T cell 
maturation (CD45RA+ and CD45RO+ as percent of CD4+ cells 
on peripheral flow cytometry), complement levels (C3, C4, and 
CH50), pneumococcal titers [post-vaccination with 23-valent 
pneumococcal polysaccharide vaccine as available as percent pro-
tective (≥1.3 μg/mL) per serotypes tested], T cell proliferation to 
mitogen (percent of CD3+ response to phytohemagglutinin and 
pokeweed) and antigen (percent of CD3+ response to Candida 
and tetanus antigens).
Unbiased network clustering analysis
A data-driven network approach was used to derive disease 
endotypes based on the presenting complications and the asso-
ciated immunophenotypes in independent cohorts: Partners 
(n =  205), USIDNET adult (n =  571), or USIDNET pediatric 
(n = 212). Accordingly, a network was constructed to model the 
inter-relationships among disease complications. Schematically, 
the model was represented as a graph, with nodes representing 
disease complications, and links between two nodes denot-
ing statistically significant correlations between two disease 
complications, quantified using chi-square statistic. In order to 
minimize uncertainties in our analysis, we excluded weaker cor-
relations with an odds ratio (OR) of less than three in the Partners 
cohort or less than two in the USIDNET and analyzed disease 
etiologies represented in less than 2% of the cohort as a larger 
group (e.g., systemic autoantibody disease). The network was then 
partitioned into subgraphs comprising highly connected nodes 
using the Girvan–Newman clustering algorithm (20). These 
subgraphs represent combinations of CVID complications with a 
high likelihood of co-occurrence. In the Partners cohort, patients 
were further assigned to individual network-derived clusters 
if they had two or more of the disease complications captured 
within that cluster. We then identified immunophenotypes that 
were significantly associated with each cluster and the association 
of each cluster with mortality using chi-square statistic. The term 
“endotype” was applied to any CVID cluster defined by a distinct 
subset of immune markers to suggest a unique immunopathol-
ogy. The term “pathophenotype” herein refers to a disease subset 
where the clinical presentation has been linked causally with an 
underlying disease mechanism.
statistical analysis
Comparative statistical analyses between cohorts were conducted 
using a two-tailed Student’s t test. Statistical analyses defining 
association within the Partners cohort were conducted using a 
chi-square test. In all analyses, a P value of <0.05 was considered 
significant.
resUlTs
comparative Demographics and 
immunophenotypes
In the USIDNET cohort, 272 patients (30.8%) were recently 
seen at an entering institution (2014–to date) whereas 612 
patients (69.2%) had a more remote visit entered in the system 
(1988–2013). By comparison in the Partners cohort, 142 patients 
(69.3%) had a recent visit in the Partners EMR (2014–to date) 
whereas 63 patients (30.7%) were seen more remotely at a 
Partners institution (1998–2013) (Figure 1A). In comparison to 
the USIDNET, there was a significantly older median age at time 
of diagnosis in the Partners cohort (Figures 1B,C, 42 vs. 24 years, 
P <  0.0001), which likely reflects the high capture of pediatric 
patients with primary immune deficiency at Boston Children’s 
Hospital (outside of the Partners network hospitals). Given the 
limitation in active follow-up and the larger fraction of pediatric 
cases in the USIDNET cohort, only 36 patients (4.1%) were 
annotated as deceased at a median of 54 years (range 25–80 years) 
compared to 31 patients (15.1%) at a median of 63 years (range 
41–83 years) in the Partners cohort at the time of review, which 
met statistical significance for older age at time of death in the 
Partners cohort (Figure 1C, P =  0.016). Gender demonstrated 
a female predominance in both cohorts, however, was increased 
comparatively in the Partners cohort at 70.7 vs. 57.1% female 
(Figure  1D, P =  0.00034). Finally, patients with an identified 
underlying CVID-associated genetic mutation were extremely 
limited in both cohorts (3.9% in Partners vs. 3.3% in USIDNET) 
with exact etiologies as shown (Figure 1E).
Immunophenotypes were highly comparable between the two 
cohorts. Native immunoglobulin levels demonstrated slightly 
FigUre 1 | Comparative demographics between the Partners and United States Immunodeficiency Network (USIDNET) common variable immunodeficiency (CVID) 
cohorts. (a) Active patient follow-up, shown as percentage of total cohort. (B) Patient age at time of diagnosis, shown as frequency by age. (c) Patient age at time 
of diagnosis or death, shown as median ±95% CI with statistical significance indicated by P value. (D) Gender distribution, shown as percentage of total cohort.  
(e) Patients with an identified mutation in a CVID-associated gene, shown as percentage of total cohort.
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lower IgG in the Partners cohort (Figure  2A, median 422 vs. 
575 mg/dL, P < 0.0001) but otherwise similar deficiencies were 
identified in IgA (median 44 vs. 25 mg/dL), IgM (median 42 vs. 
34 mg/dL), IgE (median 8 vs. 4 IU/mL), and IgG subclasses 1–4 
(median IgG1 309.5 vs. 309, IgG2 104 vs. 106.5, IgG3 21 vs. 27, 
and IgG4 4.6 vs. 7 mg/dL). These trends persisted despite extrac-
tion of the USIDNET pediatric population (immunoglobulin 
levels obtained ≤18 years of age) (Figure S1A in Supplementary 
Material). Protective titers to pneumococcus were defined as 
≥1.3 μg/mL in the Partners cohort or otherwise as annotated 
in the USIDNET. Calculated percentages of protective titers 
per pneumococcal serotypes tested were then compared across 
cohorts as previously described for the diagnostic criteria of CVID 
(1). This analysis demonstrated similar impairment in antibody 
response to pneumococcus in both cohorts (Figure 2B, median 
25.0 vs. 16.7%). Finally, lymphocyte subsets were analyzed in 
both cohorts (Partners vs. USIDNET). Absolute counts of total 
CD3+ T cells (median 935.5 vs. 1,249.25 cells/μL) and CD4+ 
FigUre 2 | Comparative immunophenotypes between the Partners and United States Immunodeficiency Network (USIDNET) common variable immunodeficiency 
(CVID) cohorts. (a) Native immunoglobulin levels, (B) protective pneumococcal vaccine (PCV) titers, (c) total lymphocyte counts, (D) B cell maturation, and (e) T cell 
maturation shown as median ± 95% CI. Number of patients reported per immune parameter shown in parentheses. Statistical significance indicated by P value.
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T cells (median 630.5 vs. 698 cells/μL) were not statistically dif-
ferent. However, absolute counts of CD8+ T cells (median 303 
vs. 431 cells/μL, P = 0.0017) and CD19+ B cells (median 124 vs. 
214 cells/μL, P = 0.018) were significantly lower in the Partners 
cohort (Figure 2C). With further extraction of the USIDNET 
pediatric population (lymphocyte counts obtained ≤18 years of 
age), this difference in CD19+ B  cells resolved (median adult 
count 180 cells/μL, P = 0.16) and the difference in CD8+ T cells 
trended toward similar (median adult count 376.5  cells/μL, 
P = 0.030) (Figure S1B in Supplementary Material), suggesting 
that increased pediatric cases contributed in part to the observa-
tion of higher total lymphocyte counts in the USIDNET. Flow 
cytometry assessment of B and T  cell maturation was limited 
in both cohorts (CD27+ IgD− staining in CD19+ B  cells 
annotated in 20.0% Partners vs. 14.0% USIDNET; CD45RA+ 
staining in CD4+ T cells annotated in 13.7% Partners vs. 11.4% 
USIDNET). Given these limitations, a similar degree of matura-
tion arrest at the level of memory (median 11.9 vs. 7.0% CD27+) 
and class-switched memory (median 2.0 vs. 2.4% CD27+ IgD−) 
was observed in the CD19+ B cell compartment (Figure 2D). 
In comparison, a similar reduction in naïve CD4+ T cell counts 
(median 22.75 vs. 26.1% CD45RA+) but with a preferential 
expansion in memory CD4+ T  cell counts (median 67.0 vs. 
27.0% CD45RO+, P <  0.0001) was observed in the Partners 
cohort (Figure 2E). This CD45RO+ CD4+ T cell expansion per-
sisted in the Partners cohort despite extraction of the USIDNET 
pediatric population, which demonstrated an expected trend 
toward increased naïve and decreased memory CD4+ T  cells 
(median adult count 34.0% CD45RO+, P =  0.00035) (Figure 
S1D in Supplementary Material).
To further identify potential late-onset combined immuno-
deficiency cases (11), low class-switched memory B cell counts 
(CD27+ IgD− ≤2% CD19+ cells) were used as a marker of severe 
B cell immunopathology as previously described for CVID (10) 
and assayed for overlapping defects in the CD4+ T cell compart-
ment. In both cohorts, there was a trend toward lower naïve CD4+ 
T cells in patients with ≤2% class-switched memory B cells, which 
met statistical significance in the Partners cohort (P <  0.0001, 
Figure 3A). Additional analysis of CD3+ T cell proliferation to 
in vitro mitogen or antigen challenge demonstrated a preferential 
defect in patients with ≤2% class-switched memory B cells fol-
lowing mitogen challenge in the Partners cohort (P =  0.0067, 
Figure  3B), whereas no difference was observed following 
mitogen challenge in the USIDNET cohort or following antigen 
challenge in either cohort (Figures 3B,C).
Together these data confirmed that in comparison to the 
national CVID registry (USIDNET), the Partners cohort had 
similar if not more severe immunopathology (lower native IgG 
levels, lower CD8+ and CD19+ lymphocyte counts, and increased 
shift toward memory CD4+ T  cells), due in part to an older 
patient demographic. Furthermore, while lack of routine B and 
T  cell immunophenotyping prohibited an accurate assessment 
of combined immunodeficiency frequency in both cohorts, the 
overlapping reduction in naïve CD4+ T cell counts and response 
to mitogen challenge in patients with ≤2% class-switched memory 
B cells in the Partners cohort was consistent with the identifica-
tion of a late-onset combined immunodeficiency phenotype.
comparative non-infectious Disease 
Outcomes
Non-infectious disease outcomes were annotated for all 205 
patients in the Partners cohort compared to only 783 patients 
who had data entry for this field in the USIDNET. As the Partners 
FigUre 3 | Overlapping B and T cell immunopathologies in the Partners and United States Immunodeficiency Network (USIDNET) common variable 
immunodeficiency (CVID) cohorts. Comparison by class-switched memory B cell severity (CD27+ IgD− ≤2% vs. >2% CD19+ cells) of (a) naïve CD4+ T cell counts 
(CD45RA+ cells shown as percent of CD4+ cells), (B) CD3+ T cell proliferation to mitogen (number (no.) of intact responses to phytohemagglutinin and pokeweed 
stimulation shown), and (c) CD3+ T cell proliferation to antigen [number (no.) of intact responses to Candida and tetanus stimulation shown]. Symbols denote 
individual patients; black bars denote median ± 95% CI. Number of patients reported per immune parameter shown in parentheses. Statistical significance indicated 
by P value.
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cohort was an older demographic at the time of diagnosis with a 
higher percentage of active patient follow-up, only four patients 
remained in the pediatric category (≤18 years of age) at the time 
of last recorded visit to a Partners institution, consistent with a 
median age of 56 years at last follow-up in the Partners cohort 
(Figures 4A–C). In contrast, 27.1% of patients in the USIDNET 
remained in the pediatric category (≤18  years of age) at the 
time of last recorded visit (Figures 4A,B). Therefore, we chose 
to analyze non-infectious disease outcomes separately in the 
USIDNET adult (n = 571, median age of 46 years at last follow-
up) and USIDNET pediatric (n = 212, median age of 12 at last 
follow-up) cohorts (Figure  4C). Moreover, as accumulation of 
non-infectious disease complications may be age-dependent (3), 
statistical comparisons were drawn only between the Partners 
and USIDNET adult cohorts.
Comparable to increased non-infectious disease rates were 
observed in the Partners cohort across all complications analyzed 
including end-organ lymphoproliferative disease, cytopenias, 
atopy, malignancy, and autoimmunity (Figures  4D–H). End-
organ lymphoproliferative disease was further subcategorized 
in the Partners cohort by disease confirmed radiographically or 
by biopsy demonstrating benign lymphoproliferative pathology. 
Specific chart review of all radiology in the Partners EMR for these 
complications likely contributed to a high capture rate, however, 
even when limited to biopsy-proven disease the Partners cohort 
had similar rates of LAD (18.0 vs. 16.8%, P =  0.69), GLILD 
(12.7 vs. 14.5%, P  =  0.51), and autoimmune gastrointestinal 
disease including AIE and IBD (21.5 vs. 17.3%, P =  0.18) and 
increased rates of granulomas (20.0 vs. 8.6%, P <  0.0001) and 
non-infectious hepatitis including autoimmune hepatitis and 
NRH (9.3 vs. 5.1%, P =  0.033) as compared to the USIDNET 
adult cohort (Figure 4D; Table S1 in Supplementary Material). 
Chronic cytopenias were also comparable to increased in the 
Partners cohort (Figure 4E; Table S2 in Supplementary Material). 
This included autoimmune cytopenias specifically: AIHA (10.7 
vs. 5.1%, P = 0.0051), ITP (13.2 vs. 8.1%, P = 0.032), and AIN 
(4.9 vs. 0.5, P < 0.0001). Here again, chart review of all cytology 
in the Partners EMR likely contributed to a high capture rate. 
Atopic disease was increased overall in the Partners cohort, with 
increased rates to the USIDNET adult population even when 
limited to asthma receiving Partners subspecialty care (49.8 vs. 
40.1%, P = 0.017), eczema receiving Partners subspecialty care 
(19.5 vs. 11.4%, P = 0.0036), or allergic rhinitis with confirmed 
positive skin testing (15.6 vs. 6.3, P < 0.0001) (Figure 4F; Table 
S3 in Supplementary Material). Hematologic malignancies were 
comparable between adult cohorts including similar frequencies 
of lymphoma (2.4 vs. 4.6%, P = 0.18) and leukemia (1.0 vs. 0.4%, 
P = 0.29) (Figure 4G; Table S4 in Supplementary Material). In 
contrast, solid organ malignancy was increased in the Partners 
cohort with major sites including the skin, cervix, breast, and lung 
(Figure 4G; Table S4 in Supplementary Material). Finally, auto-
immunity was comparable to increased in the Partners cohort 
across the spectrum of systemic autoantibody disease, inflamma-
tory arthritis, autoimmune neuropathy, cutaneous disease, and 
thyroiditis (Figure  4H; Table S5 in Supplementary Material). 
Breakdown to individual disease etiologies revealed increased 
frequency in the Partners cohort as follows: polymyalgia rheu-
matica (1.5 vs. 0.0%, P = 0.0038), seronegative arthritis (8.8 vs. 
1.9%, P < 0.0001), myasthenia gravis (1.0 vs. 0.0%, P = 0.018), 
chronic intermittent urticaria (10.7 vs. 5.4%, P =  0.0010), and 
Hashimoto’s thyroiditis (8.8 vs. 2.3%, P <  0.0001) (Figure  4H, 
Table S5 in Supplementary Material).
FigUre 4 | Continued
8
Farmer et al. CVID Endotypes by Network Clustering
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1740
non-infectious Disease endotypes  
in the Partners cohort
To further determine inter-relationships between the non-infec-
tious outcomes identified in the Partners cohort, we used unbiased 
network clustering. This analysis yielded discrete clusters that 
were predominantly lymphoproliferative (2 clusters), autoim-
mune (2 clusters), and atopic (1 cluster) in etiology (Figure 5A). 
Notable exceptions included localization of psoriasis to the atopic 
cluster, which may represent diagnostic uncertainty with eczema 
in this condition, as well as localization of bronchiectasis and 
IBD to autoimmune cluster 1, which may represent unantici-
pated autoimmune co-occurrence with these conditions (39, 40) 
and a divergence of immunopathology between IBD and AIE 
(41, 42). In contrast, localization of cytopenias and hematologic 
FigUre 5 | Unbiased network clustering of non-infectious disease complications in the Partners cohort. (a) Graph of inter-relationship among 34 non-infectious 
disease complications in the Partners cohort defined using unbiased network clustering. Nodes in the graph represent disease complications; links between nodes 
denote statistically significant relations between comorbidities; clustering of comorbidities represents disease patterns with high likelihood of co-occurrence as 
defined by the Girvan–Newman clustering algorithm (20). The weight of each network link correlates with the strength of the association between two comorbidities, 
as measured by chi-square test (P < 0.05). Nodes in isolation indicate disease complications that failed to cluster due to a lack of association with other 
comorbidities. Subgraphs are annotated as lymphoproliferative (1 and 2), autoimmune (1 and 2), and atopic (1) clusters, respectively. (B) Patient assignment by 
non-infectious disease cluster, shown as percentage of total cohort. (c) Cluster overlap, shown as a Venn diagram assembled using the web-based tool 
InteractiVenn as previously described (43). AI, autoimmune; AIE, autoimmune enteropathy; AIHA, autoimmune hemolytic anemia; autoab, auto-antibody; bx, 
biopsy-proven; CA heme, hematologic cancers; CA organ, solid organ cancers; chronic intermittent urticaria (urticaria); GLILD, granulomatous-interstitial lung 
disease; IBD, inflammatory bowel disease; LAD, lymphadenopathy; NRH, nodular regenerative hyperplasia; PH, pulmonary hypertension.
FigUre 4 | Comparative non-infectious disease complication rates between the Partners and United States Immunodeficiency Network (USIDNET) common 
variable immunodeficiency (CVID) cohorts. (a) Patient age at time of last visit, shown as frequency by age with dotted red line indicating the pediatric cutoff 
(≤18 years). (B) Adult vs. pediatric distribution at time of last visit, shown as percentage of total cohort. (c) Patient age at time of last visit, shown as median ± 95% 
CI with statistical significance indicated by P value. Frequency of (D) lymphoproliferative disease, (e) cytopenias, (F) atopic disease, (g) malignancy, and (h) 
autoimmunity, shown as percentage of total cohort with available data entry [Partners: P, n = 205; USIDNET adult: U(a), n = 571, USIDNET pediatric: U(p), n = 212]. 
Statistical significance between the Partners total and USIDNET adult cohorts is indicated for the total outcome represented in the bar (ns = not statistically different, 
*P < 0.05, **P < 0.005, ***P < 0.0001). AIE, autoimmune enteropathy; AIH, autoimmune hepatitis; AIHA, autoimmune hemolytic anemia; AIN, autoimmune 
neutropenia; APLS, antiphospholipid syndrome; CCP, cyclic citrullinated peptide; CIU, chronic intermittent urticaria; GI, gastrointestinal; GLILD, granulomatous-
interstitial lung disease; IBD, inflammatory bowel disease; ITP, immune thrombocytopenia; LAD, lymphadenopathy; LN, lymph node; MCTD, mixed connective tissue 
disease; NRH, nodular regenerative hyperplasia; pedi, pediatric; PMR, polymyalgia rheumatica; RF, rheumatoid factor.
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malignancy to lymphoproliferative cluster 2 is consistent with 
previously described coincidence of autoimmune cytopenias and 
lymphoproliferative pathology in CVID (10). Finally, solid organ 
malignancy and thyroid nodules formed an independent cluster, 
and nasal polyps were not associated with any other outcome 
analyzed, which may represent dual pathologies of eosinophilic 
and lymphocytic polyposis contained within this broader catego-
rization (Table S1 in Supplementary Material).
Next, patients were assigned to individual clusters by definition 
of having two or more outcomes contained within that cluster. 
This analysis revealed a significant burden of non-infectious 
disease across the Partners cohort with 122 patients (59.5%) 
contained within the total lymphoproliferative cluster, 55 patients 
(26.8%) contained within the total autoimmune cluster, and 70 
patients (34.1%) contained within the atopic cluster (Figure 5B). 
In contrast, 44 patients (21.5%) failed to localize to a non-infec-
tious disease cluster, consistent with an infections only phenotype 
as previously reported for CVID (3–5). Finally, analysis of patient 
overlap demonstrated cluster assignment to be highly specific 
with a maximum of 49 patients (23.9%) overlapping between 
lymphoproliferative clusters 1 and 2 (Figure 5C).
To determine whether cluster assignment correlated with 
immunophenotype, OR association with cluster assignment was 
analyzed across 25 different immune parameters. This analysis 
revealed immunophenotypic correlations that were specific 
to the lymphoproliferative, autoimmune, and atopic clusters, 
respectively (Table 1). Consistent across all lymphoproliferative 
clusters (1, 2, and in total) was an association with low class-
switched memory B  cells (CD27+ IgD− ≤2% CD19+ cells), 
low total CD19+ B cells (<90 cell/μL), and loss of naïve CD4+ 
T  cells (CD45RA+ <20% and CD45RO+ >70% CD4+ cells). 
Immunopathology associated with lymphoproliferative cluster 
2 specifically that additionally carried over to the lymphopro-
liferative cluster in total included CD4+ T  cell lymphopenia 
(<419 cell/μL), high serum IgM (>334 mg/dL), and low C3 levels 
(<93 mg/dL). These data both confirmed and expanded on previ-
ously defined associations with lymphoproliferative pathology in 
CVID [low class-switched memory B cells (10), low total B cells 
(3), high serum IgM (5, 14), and skewed CD4+ T cell matura-
tion (11, 13, 15, 17)] as well as defined a novel association (low 
C3). In contrast, none of the 25 immune parameters analyzed 
were found to be significantly associated with the autoimmune 
clusters (1, 2, or in total), and only high serum IgE (>100 IU/mL) 
significantly associated with the atopic cluster, consistent with 
previous description of high serum IgE as a marker of atopic 
disease (44, 45). In summary, these data demonstrated both vali-
dated and novel immunophenotypic correlations that were highly 
cluster-specific and entirely non-overlapping, consistent with the 
identification of distinct lymphoproliferative, autoimmune, and 
atopic CVID non-infectious disease endotypes through the use 
of unbiased network clustering.
Finally, unbiased network clustering of non-infectious disease 
complications was attempted in the USIDNET dataset. In the 
pediatric cohort (n = 212), this analysis yielded discrete atopic 
and lymphoproliferative clusters (Figure S2A in Supplementary 
Material). Of note in this population, the autoimmune cytopenias 
were strongly associated and clustered independently, and there 
was an absence of the total autoimmune disease cluster previously 
identified in the Partners cohort, likely driven by the low fre-
quency of these complications overall in the pediatric population 
(Figure 4H). In contrast, there was a lack of association between 
known comorbidities in the USIDNET adult cohort (n =  571) 
(Figure S2B in Supplementary Material). We were, therefore, 
unable to derive meaningful network clusters of non-infectious 
disease complications for the adult population.
Mortality risk in the Partners cohort
Risk of death in the Partners cohort was analyzed across all non-
infectious disease outcomes and immunophenotypes indepen-
dently as well as within the lymphoproliferative, autoimmune, 
and atopic clusters identified. For the individual non-infectious 
disease outcomes, mortality was most strongly associated with 
lymphopenia (OR 12.9, P < 0.0001), PH (OR 6.6, P < 0.0001), 
AIHA (OR 4.0, P = 0.001), and autoimmune hepatitis (OR 3.0, 
P = 0.040) in addition to thrombocytopenia, solid organ malig-
nancy, splenomegaly, and LAD (Table  2, top panel). Analysis 
of the individual immunophenotypes further delineated an 
association with CD3+ (OR 4.6, P = 0.046) and CD4+ (OR 4.5, 
P = 0.017) T cell lymphopenia in addition to low C3 (<93 mg/dL, 
OR 6.5, P = 0.015) and low median IgG while receiving replace-
ment immunoglobulin therapy (<800 mg/dL, OR 4.3, P = 0.004) 
(Table  2, middle panel). Finally, among the non-infectious 
disease endotypes identified in the Partners cohort, risk of death 
was specifically associated with lymphoproliferative cluster 2 (OR 
5.9, P < 0.0001) (Table 2, bottom panel).
DiscUssiOn
Primary immune deficiency disorders remain low frequency in 
the general population with an estimated prevalence for CVID 
of 1:10,000 to 1:100,000 (1). Therefore, primary immune defi-
ciency disease epidemiology benefits greatly from the assembly 
of national cohorts and databases such as the USIDNET. Our 
data importantly highlight the applicability of these national data 
in validating results obtained from smaller, regional cohorts. 
Here, we demonstrate the Partners CVID cohort to be a slightly 
older age demographic with increased female predominance 
as compared to the USIDNET, however, with comparable 
immunophenotype as measured by native immunoglobulin 
levels, titer response to pneumococcus, and B  cell maturation 
arrest at the memory and class-switched memory stages. The 
lower absolute lymphocyte counts identified in the Partners 
cohort, including CD19+ B  cells and CD8+ T  cells, were due 
in part to age-related changes in an older patient demographic 
(46, 47). However, we cannot exclude an additional, potentially 
bidirectional, association between the higher non-infectious 
disease complication rates and more severe immunopathology 
identified in the Partners cohort. In both CVID cohorts, there 
was a reduction in naïve CD4+ T cell counts with a trend toward 
overlapping lower class-switched memory B  cell counts that 
met statistical significance in the Partners cohort. CD4+ T cell 
dysfunction, as measured by decreased proliferation to in vitro 
mitogen stimulation, also overlapped with lower class-switched 
memory B cell counts in the Partners cohort. These data suggest 
TaBle 1 | Immunophenotype correlation with cluster assignment in the Partners cohort.
immune parameter (reference range) lymphoproliferative autoimmune atopic
cluster (1) cluster (2) cluster (total) cluster (1) cluster (2) cluster (total) cluster (1)
IgG (614–1,295 mg/dL)
IgA (69–309 mg/dL)
IgM (53–334 mg/dL) 1.9* (1.03–3.4) / 1.1* (1.02–1.14) 1.1* (1.01–1.1)
IgE (0–100 IU/mL) 6.5** (1.7–24.9)
IgG1 (382.4–928.6 mg/dL)
IgG2 (241.8–700.3 mg/dL)
IgG3 (21.8–176.1 mg/dL)
IgG4 (3.9–86.4 mg/dL)
IgG (median on replacement therapy) (800–1,400 mg/dL)
CD3+ (690–2,540 cells/μL) 5.3*** (2.0–13.9)
CD4+ (419–1590 cells/μL) 6.8*** (2.5–18.1) 4.7** (1.5–14.7)
CD8+ (190–1,140 cells/μL) 2.6* (1.05–6.6)
CD16/56+ CD3− (90–590 cells/μL)
CD19+ (90–660 cells/μL) 3.4* (1.3–8.6) 3.8* (1.4–9.8) 3.8* (1.3–11.0)
CD27+ (5–25% of CD19+)
CD27+ IgD− (2–20% of CD19+) 7.3* (1.6–33.1) 12.8*** (2.9–56.6) 9.2** (2.0–41.7)
CD45RA+ (20–70% of CD4+) 23.8*** (3.4–169.4) 3.8*** (1.8–8.1) 3.3*** (1.7–6.5)
CD45RO+ (20–70% of CD4+) 9.8* (1.6–61.6) 2.8** (1.5–5.4) 2.6* (1.4–4.6)
PHA proliferation (≥58.5% of CD3+)
PWM proliferation (≥3.5% of CD3+)
Candida proliferation (≥3.0% of CD3+)
Tetanus proliferation (≥3.3% of CD3+)
C3 (93–202 mg/dL) 11.2*** (2.9–43.3) 5.1* (1.1–24.0)
C4 (16–41 mg/dL) 6.1* (1.5–24.0)
CH50 (63–145 mg/dL)
Statistically significant correlations are shown as odds ratio with 95% confidence interval, *P < 0.05, **P < 0.005, ***P < 0.0001. Blue/red indicates an association with low/high immune parameter levels, respectively.
PHA, phytohemagglutinin; PWM, pokeweed mitogen.
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TaBle 2 | Mortality risk in the Partners cohort.
N Odds ratio (95% ci) P-value
non-infectious disease outcome
Lymphopenia 21 12.9 (5.4–30.6) <0.0001
Pulmonary hypertension 13 6.6 (2.8–15.7) <0.0001
Autoimmune hemolytic anemia 16 4.0 (1.8–8.9) 0.001
Autoimmune hepatitis 8 3.0 (1.2–7.6) 0.04
Thrombocytopenia 13 2.9 (1.3–6.6) 0.014
Splenomegaly 14 2.8 (1.3–6.2) 0.017
Solid organ cancer 12 2.8 (1.2–6.3) 0.024
Lymphadenopathy 19 2.4 (1.1–5.3) 0.04
immunophenotype
Low C3 (<93 mg/dL) 6 6.5 (1.6–26.2) 0.015
Low CD3+ T cells (<690 cells/μL) 6 4.6 (1.2–17.9) 0.045
Low CD4+ T cells (<419 cells/μL) 8 4.5 (1.4–14.2) 0.017
Low median IgG replacement level 
(<800 mg/dL)
16 4.3 (1.6–11.1) 0.004
cluster
Lymphoproliferative cluster 2 24 5.9 (2.4–14.4) <0.0001
All statistically significant positive correlations shown as number of deceased patients 
(N), odds ratio (OR), 95% confidence interval (95% CI), and P value.
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the identification of a late-onset combined immunodeficiency 
phenotype, preferentially in the Partners cohort, as previously 
described for CVID (11). However, routine clinical B and T cell 
maturation phenotyping will be necessary moving forward to 
obtain a more accurate frequency of late-onset combined immu-
nodeficiency cases.
Limitations inherent to data entry at the national level include 
lack of capture, lack of active follow-up, and non-uniform field 
entry, all of which potentially contributed to lower non-infectious 
disease complication rates in the USIDNET as compared to 
previous single-center analysis within the United States (3). The 
power of the Partners cohort included active follow-up in 69.3% 
of patients, a shared EMR amenable to web-based searches using 
natural language processing, and direct physician scoring of 
each non-infectious disease complication. Additionally, while 
Partners network hospitals are a non-national referral center for 
CVID, they are renowned national institutions with likely refer-
ral bias for the secondary non-infectious disease complications 
herein described. Finally, despite restricting non-infectious dis-
ease rate comparisons to the USIDNET adult population only, 
there was a persistent older median age at time of last visit in the 
Partners cohort (56 vs. 46 years, P < 0.0001). All of these factors 
likely contributed to the higher capture rate of non-infectious 
disease complications in the Partners cohort, best exemplified by 
the frequency of unanticipated complications that were identi-
fied, including PH and solid organ malignancy (14.6 and 22.0% 
in the Partners cohort, respectively). The occurrence of PH in 
primary immune deficiency has been limited previously to case 
reports (48, 49) and was annotated at only 0.5% in the USIDNET 
adult cohort. Solid organ malignancy has been reported at only 
5–7% in CVID cohorts previously (3, 4) and was annotated at 
only 9.1% in the USIDNET adult cohort. Furthermore, both 
outcomes were independently associated with increased risk 
of death in the Partners cohort (OR 6.6 and 2.8, respectively). 
Together these data suggest that PH and solid organ malignancy, 
including skin and cervical cancer as the major etiologies 
identified here, may be underrecognized complications in 
CVID. Consistent with these data, recent retrospective analysis 
of 1,583 pediatric PH cases identified an unexpected associa-
tion with primary immune deficiency (OR 37.9) (50). Further 
detailed analyzes are underway in the Partners cohort to deter-
mine the underlying pathophysiology and importantly, whether 
additional screening is required for these complications in the 
CVID demographic moving forward. However, the applicability 
of these findings may be limited to large tertiary care centers 
within the United States.
Unbiased network clustering has the novel potential to deci-
pher patterns of inter-relationship among seemingly distinct 
pathophenotypes in human disease (23, 24) and, therefore, 
may have unique applicability in genetically heterogeneous 
clinical entities like CVID, where risk modeling for non- 
infectious disease development remains elusive despite more 
than a decade of subcategorization by more traditional methods 
(5, 8–17). Within the Partners CVID cohort, unbiased network 
clustering successfully converged 34 non-infectious disease 
complications into discrete lymphoproliferative, autoimmune, 
and atopic patterns as well as diverged non-infectious disease 
complications that might otherwise have been clinically misclas-
sified (localizing AIHA outside of the autoimmune cluster, for 
example). Furthermore, cluster assignment was demonstrated 
to be specific (≤23.9% overlap between any two clusters) and 
associated with unique immunophenotypic markers consistent 
with CVID non-infectious disease endotypes. One limitation to 
the unbiased network clustering method used in this analysis, 
however, was the definition of association using an OR of three. 
While a high OR was specifically chosen to limit spurious cor-
relations in a small sample size, it could limit discovery of more 
subtle disease inter-relationships. Therefore, the non-infectious 
disease correlations identified in the Partners cohort are by 
definition strongly associated but not exhaustive. In contrast, 
there was a lack of association between known comorbidities 
in the adult USIDNET population, which prevented the for-
mation of a meaningful cluster network. We hypothesize that 
this lack of association between known comorbidities may be 
driven by comorbidity under-reporting, as we identified lower 
non-infectious disease complication rates in the USIDNET as 
compared to previous single-center analysis within the United 
States (3), or less accurate categorization, as we identified a 
high frequency of nonspecific diagnoses in the USIDNET (e.g., 
elevated liver function tests and chronic diarrhea) (Table S1 in 
Supplementary Material). As with any data-driven approach, 
the quality of network-based analyses is heavily dependent on 
the completeness and accuracy of the input data. Finally, in this 
study we searched the Partners EMR using natural language 
processing followed by direct physician scoring of the extracted 
data, which favors accuracy but is inherently time consuming. 
An alternative approach is to apply computational techniques, 
including machine learning and automated natural language 
processing, to streamline the process of phenotype abstraction 
from medical charts and network construction. Recent studies 
have demonstrated the feasibility of using such approaches to 
identify phenotypic patterns captured in EMRs, and their poten-
tial in expediting discovery research (51, 52). There is further 
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potential in applying computational approaches to integrate data 
from multiple sources to drive phenotype-genotype research.
Unbiased network clustering in the Partners cohort identi-
fied known as well as novel immunophenotype-non-infectious 
disease phenotype correlations. Low class-switched memory 
B cell counts (CD27+ IgD− ≤2% CD19+ cells) were strongly 
associated with all lymphoproliferative clusters as previously 
described (10). Low naïve CD4+ T  cell counts, which previ-
ously have been associated with CVID-related autoimmune 
cytopenias and end-organ lymphoproliferative pathology 
(11, 13, 17), additionally associated with all lymphoprolif-
erative clusters in the Partners cohort. The correlation between 
lymphoproliferative cluster 1 and low CD45RA+ (OR 23.8)/
high CD45RO+ (OR 9.8) was particularly impressive and 
higher in magnitude than the cluster-specific correlation 
with low class-switched memory B  cells (OR 7.3). Recently, 
decreased T cell receptor repertoire diversity was proposed as 
a primary mechanism of immunopathology in CVID patients 
with low class-switched memory B cells (53). Furthermore, the 
unmasking of monogenic causes of CVID including CTLA4 
and PIK3CD have demonstrated substantial lymphoprolifera-
tive disease burden in the context of chronic T cell activation 
through decreased regulatory cell inhibition or enhanced 
intracellular mTOR signaling, respectively (54–57). These data 
suggest that loss of naïve CD4+ T cells and skewing of the rep-
ertoire is a prominent and perhaps primary immunopathology 
in CVID-related lymphoproliferative disease development, 
consistent with a CVID subset that is enriched for late-onset 
combined immunodeficiency. Our data additionally highlight 
the potential utility of low CD45RA+ (<20% CD4+ cells) in 
subcategorizing CVID patients at risk for lymphoproliferative 
complications including LAD, granulomas, autoimmune hepa-
titis, and GLILD. Furthermore, as CVID classification by B cell 
phenotype alone was recently demonstrated to be ineffective 
in determining underlying genetic etiology (18), genotyping 
within the Partners cohort to determine whether non-infec-
tious disease endotype can predict genetic etiology will be of 
high utility in the CVID field moving forward. Finally, as the 
Partners cohort is actively followed, naïve CD4+ T cell counts 
and receptor repertoire can be trended over clinical course 
to determine whether loss co-occurs with or rather predates, 
and thus predicts, lymphoproliferative disease development in 
CVID.
The additional observation of low complement levels in 
association with lymphoproliferative cluster 2 (C3, OR 11.2 and 
C4, OR 6.1) as well as with the lymphoproliferative cluster in 
total (C3, OR 5.1) was unexpected and not to our knowledge 
described previously. In contrast, increased levels of C3 and C4 
were identified in a total CVID cohort comprised of 71 patients, 
41% with autoimmune disease and 13% with granulomatous 
disease, as compared to 30 healthy controls (58). Together these 
data suggest that low serum levels of C3 and C4 may be uniquely 
useful in subcategorizing CVID patients at risk for non-
infectious complications including AIE, cytopenias (AIHA), 
and NRH. Autoantibodies are known to directly mediate the 
pathology of autoimmune cytopenias, which can include clas-
sical complement activation in AIHA (59), ITP (60), and AIN 
(61). More recently, autoantibodies have been described in AIE 
(42) and NRH (62), although their role in disease pathogenesis 
is less clear. In CVID specifically, a break in central B cell toler-
ance driving autoantibody production has been described (63) 
and correlated with underlying genetic etiology in the case of 
monoallelic TNFRS13B (encoding TACI) mutations (64). As 
lymphoproliferative cluster 2 and low C3 levels were indepen-
dently correlated with increased risk of death in the Partners 
cohort (OR 5.9 and 6.5, respectively), these data suggest a 
clinically important immunopathologic distinction. Further 
research is necessary in the Partners cohort to determine 
whether the immunopathology in lymphoproliferative cluster 
2 converges at a break in B cell tolerance and/or is defined by 
underlying genetic risk.
Finally, in contrast to the lymphoproliferative and atopic cor-
relations identified, none of the examined immune parameters 
significantly correlated with the autoimmune clusters (1, 2, or 
in total). This finding suggests a CVID subset with significant 
pathology that is poorly immunophenotyped by the currently 
available routine clinical parameters. Therefore, screening for 
novel biomarker associations within this autoimmune subset, 
specifically, would be of high utility in the CVID field moving 
forward.
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